

Index

a

- Adjusted present value (APV) 145
- Alliances 1–5, 19–22, 30–31, 42–43, 45–51, 53, 61–63, 66, 70–74, 77, 87, 90, 95, 101, 108, 110, 115, 117–118, 120–122, 128
- Advantages/disadvantages 45, 47, 49, 121–122
- Early stage 61–63
- Entrepreneurs' perspectives 45
- Late stage 70–72, 126
- Other investors' perspectives 49
- Research collaborations 50–51
- Venture capitalists' perspectives 47
- Alternative Investment Market (AIM) 21–22, 51–52, 76–77, 126–127, 145
- American Research and Development (ARD) 10
- Anglo-American culture 45, 50, 82, 84, 120
- Antibody 59, 98–99, 111, 125, 145–146
- Anti-inflammatory antibody 98
- Anti-dilution provision 67–68, 123, 146
- Antigen 93, 98, 109–111, 146
- Identification program 109–110
- Atypical silent partnership 4, 43–44, 49, 64, 94, 106, 108, 114, 127, 146
- Austrianova Biomanufacturing AG 87–90, 133–134
- Austrian public funds 106
- AWS 99, 106, 112–114
- FFF 106
- FFG 98–99, 114
- WWFF 106
- AVIR Green Hills Biotechnology AG 90–96, 112, 127, 133–134

b

- Banks, role as capital investors 73
- Bioencapsulation 88–89
- Biological entity 15, 18, 112

- Biotech application 14
- Agriculture 14
- Crop production 14
- Health care 14
- Nonfood products 14
- Biotech companies 2, 16–23, 30, 49–50, 52–54, 57, 59, 62, 72, 74, 77–78, 80, 90, 108, 117, 120, 122, 127–128, 131
- Biotech case studies 87–116
- Failure causes 78–80
- Genentech 16–17
- Success stories 77–78
- Biotech drug development 14–16, 60–61
- Biotech entrepreneur, checklists 118–124
- Biotech industry 1, 5, 14–26, 35–36, 40, 44, 58, 108, 111, 119, 146
- Challenges 23
- Definition 14–16
- Development 14–26
- Exit routes 22–32
- Financing 18–22
- Future 23–26
- History 16–18
- Biotechnology 2, 14–15, 17, 19, 24–25, 28, 30–31, 35, 48, 51, 72, 77, 82, 87, 90–91, 93–98, 102–103, 112, 115, 127–128, 133–134, 146, 162
- Biotech research areas 58–61, 122
- Determinants of success 122
- Medical technology and devices 60–61
- Vaccines 59–60
- Biotech start-up
- best-practice countries for funding 80–82
- favorable climate 123–124
- primary causes of failure 78–80
- Board of directors 68–70, 84, 123, 133, 146
- Entrepreneurs' perspectives 68
- Other investors' perspectives 69–70
- Structuring 68, 123

- Venture capitalists' perspectives 68–69
- Business angels 1, 4, 18, 29–30, 45, 49–50, 52, 61, 63, 65–67, 71, 82, 85, 108, 120, 122–124, 126–128, 132, 145, 150
- Entrepreneurs' perspectives 66
- Networks 126, 132
- Other investors' perspectives 67
- Role 65–66
- Venture capitalists' perspectives 66–67
- Business model 41–42, 51, 54, 58–59, 72, 74, 102, 119, 122, 125, 128, 147
- Business plan 2, 38, 41, 46, 61–62, 64, 76, 112, 119, 121–122, 125, 147, 150
- Buy-outs 7–8, 10–12, 158

c

- Cash flow 10–11, 54–58, 72, 111, 125, 147, 149, 154–155, 158
- Center of Private Equity Research (CEPRES) 13, 147
- C5a antagonist project 97, 99
 - Development 97
- Challenge study 94, 96, 134, 148
- Checklists 118–127
 - Biotech entrepreneurs 118–124
 - Investors 124–127
- Chronic inflammatory diseases 113
 - Periodontitis 113
- Clinical trial program 14–16, 45, 60, 125
- Coding frame 34
- Collaborative research program 25
- Comparable methods 54–55, 57
- Contract research 32, 50–51, 115, 122, 128
- Convertible preferred (CP) stock 123, 148
- Copenhagen Stock Market (CSE) 21–22
- Corporate memory 46, 121
- Corporate venture capital (CVC) 4, 8, 42–43, 46, 48, 50, 72, 108, 120, 148
- Corporate venture capitalist 52, 71–72, 122, 126, 128
- Cost of capital 148–149, 155, 158
- Cross-protective immunity 91

d

- Data analysis 35–85
- Data interpretation 35–85
- Deal structure 67–68, 123
 - Convertible preferred shares 67–68, 123, 148
 - Deal preference 123
 - Liquidation preference 23, 67–68, 123, 154
- DeltaFlu 91–92, 94, 96, 134
- Delta NS1 technology 92, 156

- Discounted cash flow (DCF) methods 4, 54–57, 125, 149
 - Calculation 54–55
- Drug development process 14–16, 29
 - Returns 29
 - Risk 29
- Drug's pharmaceutical efficacy 15–16

e

- Early-stage financing 1, 48–49, 52–53, 57, 120, 127, 150, 154
- Early-stage funding 61–63
 - Entrepreneurs' perspectives 62
 - Other investors' perspectives 62–63
 - Venture capitalists' perspectives 62
- Early-stage venture capitalists 1, 18, 29–30, 49, 120, 150
- Earnings before interest and taxes (EBIT) 150
- Earnings before interest, taxes, depreciation, amortization (EBITDA) 150
- Entrepreneur(s) 2–5, 27–32, 35–54, 58, 61–70, 72–76, 78–80, 82–85, 117–125, 128, 131, 132, 145–146, 151, 153, 160–161
 - Checklists 118–124
 - Dilemma 27
 - Dual role 37–38, 119
 - Major characteristics 36–37
 - Perspectives 41, 43–45, 49–50, 62, 64, 66, 68–69, 72, 75, 78, 80, 82–85
 - Practical guidelines 30
 - Qualitative interviews 31
 - Selection criteria 31–32
- Entrepreneurship 27–28, 38, 62, 64, 102, 117, 151, 153, 160
 - Definition 27
- EUCODIS GmbH 96–103, 133
 - EUCODIS Bioscience 98–100, 102–103
 - EUCODIS Pharmaceuticals 98, 100
- European Association of Bioindustries 14
- European biotech companies 18–20, 23, 49, 120, 128
 - Challenges 23
 - Funding mechanisms 120
 - Future perspectives 23
 - Pipeline 18–19
- European Commission 23, 40, 93, 119
- European Medicines Agency (EMA) 23, 88, 151, 157
- European research area (ERA) 25, 93
- European stock exchanges 51–52
- European Union (EU) grants 4, 43, 46–48, 50, 120
- European Union research framework program 23, 25–26, 93, 95, 99

- Evolution 26
- European venture capital 7, 9–10, 13, 21, 32, 40, 82–85, 151
- Funds 40
- Future 13–14
- Market 13, 40, 82–85
- Performance 12–13
- European Venture Capital Association (EVCA) 7, 9–10, 13, 40, 54, 67, 151
- Evaluation of results 33–34
- Exit routes 22, 74–76
 - Entrepreneurs’ perspectives 75
 - Other investors’ perspectives 76
 - Venture capitalists’ perspectives 75–76

f

- FFG 98–99, 114
- Fibrodystrophia ossificans progressiva (FOP) 97, 99
- Financing model matrix 28–30, 42–50, 120, 127
 - Strengths/drawbacks 44–50
 - Entrepreneurs’ perspectives 43–44
 - Other investors’ perspectives 47
 - Primary financing form 120
 - Venture capitalists’ perspectives 45–46
- Financing, new and creative approaches 50, 122
- Flavivirus 151
- FluVacc technology 92
- Food and Drug Administration (FDA) 16–17, 104, 134, 152, 155
- FP6, *see* Sixth framework program
- FP7, *see* Seventh framework program
- Frankfurt stock exchange (FSE) 21–22
- Free cash flow (FCF) 54, 152
- Fund(s) 3–4, 8–12, 18, 25, 32, 36, 39–40, 42, 45–49, 53, 62, 64, 71–73, 81–82, 89, 93, 95, 100–102, 106, 108, 114–115, 117, 119–121, 123, 126, 128, 147, 150, 152, 154, 161
- Funding biotech start-ups 80–82
 - Best-practice countries 80–82
 - Entrepreneurs’ perspectives 80
 - Other investors’ perspectives 81–82
 - Venture capitalists’ perspectives 81

g

- General partners (GP) 8, 152, 154, 162
- GlaxoSmithKline SR-One Fund 4, 8
- Global economy 11, 18
- Global equity markets 12
- Global funds 39–40, 119–120
 - Advantages 39–40

- Good Manufacturing Practice (GMP) 89, 152
- Government funding organizations 36, 45, 123
- (Government) grants 3–4, 43, 45–49, 63–64, 121, 131, 152
 - Advantages/disadvantages 45, 47, 48, 121
 - Entrepreneurs’ perspectives 64
 - Other investors’ perspectives 65
 - Role 63–64
 - Venture capitalists’ perspectives 64–65
- Gross domestic product (GDP) 13, 153

h

- Hepatitis C virus vaccine 77, 109–110
- Hermeneutics, circle 33, 128
- High net worth individuals 50–51, 122, 127, 131
- High-risk business opportunities 131
- Human Monoclonal Antibodies for a Library of Hybridomas (HYBLIB) 99

i

- Incubator(s) 52–53, 61, 108, 123, 153
- Industrial biotechnology, *see* white biotechnology
- Inflammatory disorders 98
- Influenza virus 91–94, 113, 153
 - FluVacc 91–93, 134
 - Market 91
 - Vaccine 91, 94, 112
- Information-seeking process 33
- Initial public offering (IPO) 1, 4–5, 8–9, 11, 19–23, 30, 48, 53, 56, 69, 73, 75–77, 96, 106, 145, 153, 155
 - Market 22–23
 - Success stories 77–78
- Institutional investors 8, 114, 145
- Intellectual property (IP) 41–42, 58, 62, 106, 110, 122, 135, 153
- Intercell AG 59, 77, 88, 102–111, 133–135
 - Product pipeline 105
- Internal rate of return (IRR) 153
- Interviews, qualitative 2, 31–34, 87
 - Evaluation of results 33–34
- Interview partners 2, 4, 31–33, 35–36, 38–40, 43, 48–50, 52, 56, 58–60, 63, 67–69, 73–74, 76–77, 80, 82, 84, 119, 122–123, 127–128
 - Description 35–36
 - Entrepreneurs 35
 - Other investors 36
 - Selection 31–33
 - Venture capitalists 36
- Investments 7–8

- Expansion-stage 7–8
- Replacement capital 7–8
- Seed-stage 7
- Start-up 7
- Investor(s) 2, 4, 7–13, 18, 20–22, 28, 31–33, 36, 39–42, 44, 46–56, 60–69, 71–73, 75, 78–85, 98, 101–102, 106, 108, 110, 114–116, 118–129, 131, 145–146, 149–151, 154, 156, 159–161
- Dilemma 28
- Entry criterion 118–119
- Other investors' perspectives 42, 47–50, 62–63, 65, 67, 69–72, 76, 79–85
- Selection criteria 31–33
- Types 9, 29–30, 52

j

- Japanese encephalitis (JE) 77, 104–105, 109–110, 135
- virus vaccine 77, 104–105, 109–111
- Joint research centre (JRC) 25

l

- Late-stage financing 32–33, 36, 52–53, 56–57, 153
- Late-stage funding 70–72
- Late-stage venture capitalists 1, 19, 29–30, 153
- Leveraged buy-outs (LBOs) 8, 10, 154–155, 158
- Limited partners (LP) 8, 14, 28, 154
- Liquidation 54, 68, 123, 146, 148–149, 154, 158–159
- Liquidation preference 23, 67–68, 123, 154
- London stock exchange (LSE) 21–22, 76, 145

m

- Management buy-in (MBI) 155
- Management buy-out (MBO) 1, 9–10, 30, 153, 155
- Market capitalization 17, 19, 21–22, 75, 155
- Massachusetts Institute of Technology 10
- Massachusetts Investors Trust 10
- Medical technology and devices 60–61
- MelVir diagnostic tool 93
- Mergers and acquisitions (M&A) 9–10, 155
- MERV-derived antigens 93
- Mezzanine 4, 7–8, 42–43, 46, 48, 50, 53, 73, 108, 120, 155, 158
- Money 8
- Investors 8
- Milestone payments 74, 110, 155
- Importance 74
- Monte Carlo method 56–57, 155

- Mosquito-borne flaviviral infection 104
- Japanese encephalitis (JE) 104–105
- Multiples 55, 58, 125, 155

n

- National Institutes of Health (NIH) 60, 99, 126
- Net present value (NPV) 56, 145, 153, 155
- Networking 2, 5, 28, 30, 37–38, 41, 61–63, 69–71, 77, 95, 115–117, 125, 156, 158
- Business angel 70
- Corporate venture capitalists 70
- Early-stage alliances 61–63
 - Entrepreneurs' perspectives 62
 - Other investors' perspectives 62–63
 - Venture capitalists' perspectives 62
- Late-stage alliances 70–72
 - Entrepreneurs' perspectives 72
 - Other investors' perspectives 70–72
 - Venture capitalists' perspectives 70–72
- “Neuer Markt” 52
- New chemical entity (NCE) 14–15, 35, 156
- Product development cycle 15
- New markets, role 50–52, 76–77, 126–127
- Non-profit organizations (NPO) 43, 46, 48, 60, 151–152, 156
- NovaCaps® technology 88–90
- Novartis Venture Funds 4, 8, 59, 72

o

- onepharm Research & Development GmbH 111–116, 133, 135–136
- Other investors 36
 - Perspectives 42, 47–50, 62–63, 65, 67, 69–72, 76, 79–85
 - Qualitative interviews 31
 - Selection criteria 31–33

p

- Pandemic influenza 92–93, 134–135
- Partnering criteria 40–42
 - Entrepreneurs' perspectives 41
 - Other investors' perspectives 42
 - Venture capitalists' perspectives 41–42
- Partnership 4, 39, 43–44, 49, 60, 72, 78, 89, 94–95, 99–101, 106, 108–111, 114, 117–118, 120, 123–124, 126, 132, 146, 148, 152, 157, 161
- Personalized medicine 59, 122, 157
- Pharmaceutical players 3, 45, 71–72, 90
- Pipeline, biotech companies, listed 18
- Pipeline, biotech companies, not listed 19
- Polymerase chain reaction (PCR) 17
- Practical guidelines 30

- Preclinical/clinical data 15–16, 44, 114, 134
 Preferred deal structure 67–68, 123
 Price-earnings (P/E) ratio 55, 158
 Primary causes of failure 78–80, 123
 – Entrepreneurs’ perspectives 78
 – Other investors’ perspectives 79–80
 – Venture capitalists’ perspectives 78
 Private equity 1, 7–14, 23, 33, 36, 40, 42–43, 46, 48–49, 81–82, 87, 115, 118, 120–121, 123–124, 127–128, 131–132, 147–148, 151–152, 155, 158
 – Challenges 12
 – Definition 7–10
 – Future 13–14
 – Historical background 10–12
 – Performance 12–13
 – Performance index (CepreX) 13–14
 Private equity firm(s) 7–12, 40, 158
 – Kohlberg Kravis Roberts (KKR) 10–11
 Private equity investors 8–9, 11–12
 Private equity market 7–8, 13, 147
 – Future perspectives 13–14
 Project financing 50–51, 122, 128
- q**
 Quality assurance 104, 116, 159
 Questionnaire 5, 31, 36–39, 42, 50, 58, 61, 63, 65, 70, 74–75, 77, 82, 167–186
 – Entrepreneurs 167–172
 – Other investors 180–186
 – Venture capitalists 173–179
- r**
 Real options method 56–58, 159
 Recombinant biological products 17
 – Erythropoietin 17
 – Human growth factors 17
 – Insulin 17
 – Interferons 17
 – Monoclonal antibodies 17, 96, 110
 Red biotechnology 14, 97, 102–103, 159
 Regional funds 39–40, 119
 Relationship risk-return 29, 53
 Research collaboration alliances 50–51, 122, 128
 Research & Development (R&D) 1, 4, 18, 39, 59–60, 74, 104, 124
 – Expenses 18
 – Investments 18
 – Vaccines 59–60
 Research, development and innovation (R&D&I) 26, 98
 – Framework 26
 – Investments 26
- Research goal 27
 – Entrepreneur’s dilemma 27–28
 – Financing models 28–30
 – Interpersonal relationships/cooperations 30
 – Investor’s dilemma 28
 – Practical guidelines 30
 Respiratory tract viral diseases 113
 Retrovirus 93
 Risk-taking capacity 84
- s**
 Secondary valuation method 55
 Seed-stage capital 7
 Seventh framework program (FP7) 23–26, 99
 Silent partnership 4, 43–44, 49, 106, 108, 114, 120, 146
 Sixth framework program (FP6) 26, 93, 95
 Small and medium-sized companies, new stock markets 50–52
 Socio-scientific paraphrase technique 33
 Spin-off 4, 27, 32, 35, 62–63, 87–88, 96, 103, 117, 160
 Start-up company(ies) 1–2, 8, 18–19, 23–31, 37, 42, 48, 54–55, 59, 65, 73, 77–83, 88, 93, 95, 99, 101, 112–114, 121, 132, 160
 Start-up capital 3, 7, 45, 47
 Stock market flotation 9, 160
 Strategic alliance(s) 28, 42–43, 45–49, 96, 101, 103, 121–122, 160
 Study conducting 31–34
 Swiss exchange 21–22
- t**
 Trade sale 1, 4–5, 8–9, 22, 28, 30, 33, 74–76, 153, 161
 Turnarounds 7–8, 161
- u**
 Unique selling proposition (USP) 42, 161
 US venture capital market 82–85
- v**
 Vaccines 17, 23, 35, 58–60, 77, 91–92, 96, 103–106, 109–112, 122, 125–126, 134–135, 148, 159, 162
 – Differences to classic biotech 125–126
 – Research & development 59–60
 Vaccines manufacturers 77
 – Cytos 77
 – GlaxoSmithKline 4, 59, 71, 77, 99
 – Intercell 59, 77, 88, 102–110, 133–135
 – Novartis 4, 8, 17, 51, 59, 71–72, 77, 97, 104–106, 109, 111

- Sanofi-Aventis 59, 77, 97, 99, 109
 - Valuation techniques 4, 53–58, 125
 - Early-stage 53–58
 - Late-stage 53–58
 - Venture capital 1–5, 7–13, 17, 20–21, 23, 32–33, 35–36, 40, 42–50 55–57, 62, 70, 81–85, 94–95, 98, 100, 106, 117–125, 127–128, 131–132, 147–148, 151–152, 156, 158, 160–162
 - Advantages/disadvantages 44, 46–48, 120–121
 - Entrepreneurs’ perspectives 44
 - Other investors’ perspectives 47–48
 - Venture capitalists’ perspectives 46–47
 - Venture capital companies 32, 46, 49, 62, 108, 122–123
 - Venture capital funds 8, 11, 23, 36, 40, 72, 82, 108, 119, 121, 152
 - Venture capitalists 1–5, 7, 11, 18–19, 23, 28, 30–33, 36, 38–42, 44, 46, 48–49, 52–53, 56, 61–73, 75–76, 78–79, 81–82, 84, 87, 95, 102, 106, 116–118, 120, 122–128, 131, 145, 150, 153–154, 162
 - Checklists 124–127
 - Major characteristics 38–39
 - Perspectives 41, 45–47, 49–50, 62, 64–72, 75–76, 78–79, 80–85
 - Practical guidelines 30
 - Qualitative interviews 31
 - Selection criteria 31–33
 - Venture capital markets 1, 7–14, 40, 82–85
 - Definition 7–10
 - Differences between US and Europe 82–85
 - Future perspectives 13–14
 - Historical background 10–12
 - Performance 12–13
 - Venture capital method 4, 55–57, 125
 - Vero cells 94, 162
 - Vesting period 67, 162
 - Viral engineering product line 91
 - Viral engineering technology 91
- w**
- White biotechnology 14, 35, 97–98, 103, 162
 - Wild-type viruses 92
 - World-Health Organization (WHO) 162
- z**
- ZIT center for innovation and technology 99, 114